

**PB 63 of 2025**

**National Health (Price and Special Patient Contribution) Amendment Determination (No. 5) 2025**

I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following Determination:

Dated 29 May 2025

**REBECCA RICHARDSON**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health, Disability and Aging

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022) 2

1 Name

This instrument is the *National Health (Price and Special Patient Contribution) Amendment Determination (No. 5) 2025*.

This instrument may also be cited as PB 63 of 2025.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 June 2025 |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under section 85B of the *National Health Act 1953.*

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

**Schedule 1 – Amendments**

***National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022)***

1. Schedule 1 – entry for Fluticasone propionate with salmeterol

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 125/25 | 1 | 27.07 | 30.79 |
|  | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 250/25 | 1 | 36.65 | 40.37 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by Mouth | Seretide Accuhaler 100/50 | 1 | 28.34 | 32.06 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by Mouth | Seretide Accuhaler 250/50 | 1 | 27.07 | 30.79 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by Mouth | Seretide Accuhaler 500/50 | 1 | 36.65 | 40.37 |
|  | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 50/25 | 1 | 28.34 | 32.06 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 125/25 | 1 | 27.07 | 31.72 |
|  | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 250/25 | 1 | 36.65 | 40.37 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by Mouth | Seretide Accuhaler 100/50 | 1 | 28.34 | 32.06 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by Mouth | Seretide Accuhaler 250/50 | 1 | 27.07 | 31.72 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by Mouth | Seretide Accuhaler 500/50 | 1 | 36.65 | 40.37 |
|  | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Seretide MDI 50/25 | 1 | 28.34 | 32.06 |

2. Schedule 1 – entry for Olmesartan with amlodipine and hydrochlorothiazide

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 20/5/12.5 | 30 | 5.57 | 8.36 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/5/12.5 | 30 | 8.21 | 10.65 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/5/25 | 30 | 9.66 | 12.15 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/10/12.5 | 30 | 8.59 | 12.56 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/10/25 | 30 | 10.02 | 12.50 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 20/5/12.5 | 30 | 5.57 | 9.29 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/5/12.5 | 30 | 8.21 | 11.93 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/5/25 | 30 | 9.66 | 13.38 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/10/12.5 | 30 | 8.59 | 12.56 |
|  | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/10/25 | 30 | 10.02 | 13.74 |

1. Schedule 1 – omit entry for Paraffin